Inventor · disambiguated record
Rodney Monroy
Also filed as: MONROY RODNEY · MONROY RODNEY L
22 granted patents·17 pending applications·128 citations·filing 1993–2025
94Inventor score
Files withXENOTHERAPEUTICS INC16NUVASIVE INC5BIOTRANSPLANT INC4DANILKOVITCH ALLA3MESOBLAST INT SARL3
Top patents by PatentIndex Score
39 records- 0193US11821004B2Mesenchymal stem cells expressing TNF-α receptorsMESOBLAST INT SARL·Filed 2020·Granted Nov 21, 2023·3 cites·13 claims
- 0290US10883084B2Personalized cells, tissues, and organs for transplantation from a humanized, bespoke, designated-pathogen free, (non-human) donor and methods and products relating to sameXENOTHERAPEUTICS INC·Filed 2020·Granted Jan 5, 2021·2 cites·20 claims
- 0390US8486695B2Mesenchymal stem cells expressing TNF-alpha receptorsDANILKOVITCH ALLA·Filed 2012·Granted Jul 16, 2013·33 cites·5 claims
- 0488US11833270B2Xenotransplantation products and methodsXENOTHERAPEUTICS INC·Filed 2021·Granted Dec 5, 2023·1 cites·22 claims
- 0587US11473062B2Personalized cells, tissues, and organs for transplantation from a humanized, bespoke, designated-pathogen free, (non-human) donor and methods and products relating to sameXENOTHERAPEUTICS INC·Filed 2021·Granted Oct 18, 2022·1 cites·21 claims
- 0685US11155788B2Personalized cells, tissues, and organs for transplantation from a humanized, bespoke, designated-pathogen free, (non-human) donor and methods and products relating to sameXENOTHERAPEUTICS INC·Filed 2021·Granted Oct 26, 2021·1 cites·20 claims
- 0785US11028371B2Personalized cells, tissues, and organs for transplantation from a humanized, bespoke, designated-pathogen free, (non-human) donor and methods and products relating to sameXENOTHERAPEUTICS INC·Filed 2020·Granted Jun 8, 2021·1 cites·20 claims
- 0885US6730230B2Use of high density microparticles for removal of pathogensMILTENYI BIOTEC GMBH·Filed 2002·Granted May 4, 2004·27 cites·28 claims
- 0984US2024301356A1Mesenchymal stem cells expressing tnf-alpha receptorsMESOBLAST INT SARL·Filed 2023·Application pending·0 cites
- 1082US10799614B2Xenotransplantation products and methodsXENOTHERAPEUTICS INC·Filed 2019·Granted Oct 13, 2020·1 cites·16 claims
- 1182US2025333711A1Personalized cells, tissues, and organs for transplantation from a humanized, bespoke, designated-pathogen free, (non-human) donor and methods and products relating to sameXENOTHERAPEUTICS INC·Filed 2025·Application pending·0 cites
- 1278US12297458B2Personalized cells, tissues, and organs for transplantation from a humanized, bespoke, designated-pathogen free, (non-human) donor and methods and products relating to sameXENOTHERAPEUTICS INC·Filed 2022·Granted May 13, 2025·0 cites·20 claims
- 1376US5863528APorcine cytokinesBIOTRANSPLANT INC·Filed 1995·Granted Jan 26, 1999·23 cites·42 claims
- 1473US2023274795A1Method, system, and product for refining an artificial intelligence model for predicting xenotransplantation compatabilityXENOTHERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 1571US11129922B2Xenotransplantation products and methodsXENOTHERAPEUTICS INC·Filed 2020·Granted Sep 28, 2021·0 cites·18 claims
- 1671US10905799B2Xenotransplantation products and methodsXENOTHERAPEUTICS INC·Filed 2020·Granted Feb 2, 2021·0 cites·19 claims
- 1771US8460860B2Cancellous bone treated with collagenase and essentially free of blood cellsWILLIAMS MICHELLE LEROUX·Filed 2007·Granted Jun 11, 2013·12 cites·8 claims
- 1870US11471560B2Cancellous bone product including viable osteogenic cellsNUVASIVE INC·Filed 2019·Granted Oct 18, 2022·0 cites·19 claims
- 1969US10507265B2Cancellous bone product including viable osteogenic cellsNUVASIVE INC·Filed 2017·Granted Dec 17, 2019·1 cites·16 claims
- 2069US2023323400A1Immunologically compatible cells, tissues, organs, and methods for transplantation for silencing, humanization, and personalization with minimized collateral genomic disruptionsXENOTHERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 2168US11865227B2Cancellous bone product including viable osteogenic cellsNUVASIVE INC·Filed 2020·Granted Jan 9, 2024·0 cites·17 claims
- 2265US10898611B2Cancellous bone product including viable osteogenic cellsNUVASIVE INC·Filed 2017·Granted Jan 26, 2021·1 cites·22 claims
- 2365US2024075186A1Xenotransplantation products and methodsXENOTHERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 2464US2022053739A1Immunologically compatible cells, tissues, organs, and methods for transplantation for silencing, humanization, and personalization with minimized collateral genomic disruptionsXENOTHERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 2563US2022406409A1Selection and Monitoring Methods for XenotransplantationXENOTHERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 2662US2018087032A1Mesenchymal stem cells expressing tnf-alpha receptorsMESOBLAST INT SARL·Filed 2017·Application pending·0 cites
- 2761US11424007B2Selection and monitoring methods for xenotransplantationXENOTHERAPEUTICS INC·Filed 2021·Granted Aug 23, 2022·0 cites·28 claims
- 2861US2015004693A1Mesenchymal Stem Cells Expressing TNF-alpha ReceptorsMESOBLAST INTERNAT SARL·Filed 2014·Application pending·0 cites
- 2960US2013259841A1Mesenchymal Stem Cells Expressing TNF-alpha ReceptorsOSIRIS THERAPEUTICS INC·Filed 2013·Application pending·0 cites
- 3060US2014248244A1Mesenchymal Stem Cells Expressing TNF-alpha ReceptorsMESOBLAST INTERNAT SARL·Filed 2014·Application pending·0 cites
- 3159US2007258963A1Mesenchymal stem cells expressing TNF-alpha receptorsOSIRIS THERAPEUTICS INC·Filed 2007·Application pending·0 cites
- 3257US2014056857A1Cancellous Bone Treated with Collagenase and Essentially Free of Blood CellsNUVASIVE INC·Filed 2013·Application pending·0 cites
- 3357US2009169522A1Mesenchymal stem cells expressing tnf-a receptorDANILKOVITCH ALLA·Filed 2007·Application pending·0 cites
- 3456US5858963AInducing xenograft tolerance and porcine cytokines thereforBIOTRANSPLANT INC·Filed 1995·Granted Jan 12, 1999·7 cites·10 claims
- 3554US2008262633A1Cancellous bone treated with collagenase and essentially free of blood cellsWILLIAMS MICHELLE LEROUX·Filed 2008·Application pending·0 cites
- 3653US2011189768A1Mesenchymal Stem Cells Expressing TNF-alpha ReceptorsDANILKOVITCH ALLA·Filed 2011·Application pending·0 cites
- 3750US5589582APolynucleotides en coding porcine cytokinesBIOTRANSPLANT INC·Filed 1993·Granted Dec 31, 1996·11 cites·31 claims
- 3836US5962644APorcine CD34BIOTRANSPLANT INC·Filed 1995·Granted Oct 5, 1999·3 cites·17 claims
- 3936US2002058030A1Whole blood separator apparatus and method of useELIGIX INC·Filed 2001·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Rodney Monroy files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →